-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 4, the official website of CDE showed that Hebei Renhe Yikang Pharmaceutical's dexmedetomidine hydrochloride injection was accepted as imitation 3 types.
Data show that dexmedetomidine hydrochloride is a relatively selective α2-adrenergic receptor agonist, which is suitable for tracheal intubation and sedation during mechanical ventilation in surgical patients undergoing general anesthesia, and is used during intensive care treatment.
Sales of terminal dexmedetomidine injections in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
Source: MED2.
In terms of consistency evaluation, dexmedetomidine hydrochloride injection has been evaluated by 8 companies.
Source: MED2.
Up to now, 8 companies including Nanjing Zhengda Tianqing Pharmaceutical, CSPC Yinhu Pharmaceutical, Jiangsu Zhengda Qingjiang Pharmaceutical and other 8 companies have submitted listing applications for generic 3 types of dexmedetomidine hydrochloride injection and are under review and approval (in the Center for Drug Evaluation) ); Dexmedetomidine Hydrochloride and Sodium Chloride Injection has Yangzijiang Pharmaceutical Group, Hunan Kelun Pharmaceutical, and Chengdu Beite Pharmaceutical to submit marketing applications for imitation 3 types and are under review (in the Center for Drug Evaluation).
Source: CDE official website, Minet database
